AstraZeneca plc (ADR): 1 Struggling Big Pharma Hoping to Hit the Acquisitions Jackpot

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

AstraZeneca's (NYSE: AZN  ) in a serious pickle. The company's facing the danger of major patent expirations in the near future, with the loss of protection on blockbuster drug Nexium coming in May. Nexium sold more than $2.2 billion in the U.S. alone in 2012, and with future patent losses looming in the near future -- none bigger than that of fellow blockbuster Crestor, which made more than $3 billion in U.S. revenue in 2012 -- AstraZeneca's scrambling to secure new sources of sales before big hits arrive.

One tried-and-true way to add potential quickly is through acquisitions, and this is one area that AstraZeneca's not shying away from. The company's reportedly one of a few firms interested in bidding for South Korean firm Celltrion, a maker of biosimilars. However, AstraZeneca's not the only big name competing for this buy: Both generics king Teva Pharmaceuticals (NYSE: TEVA  ) and big pharma competitor Roche (NASDAQOTH: RHHBY  )  are also in the hunt for Celltrion.

Is this the big buy AstraZeneca investors have been looking for? Find out in the video below, where Motley Fool contributor Dan Carroll takes you through what you need to know about AstraZeneca's interest in Celltrion -- and whether or not it's the right company to address the firm's financial uncertainty.

How biotech can revolutionize cancer treatments-and your financial future
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2791761, ~/Articles/ArticleHandler.aspx, 8/30/2015 2:06:50 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Carroll

Dan began writing for the Motley Fool in 2012. He is a health care specialist who also follows the defense industry along with tracking the broader U.S. and international markets.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:05 PM
AZN $31.67 Up +0.06 +0.19%
AstraZeneca plc (A… CAPS Rating: ****
RHHBY $34.16 Down -0.69 -1.98%
Roche Holding Ltd.… CAPS Rating: *****
TEVA $65.03 Down -0.17 -0.26%
Teva Pharmaceutica… CAPS Rating: ****